Pelthos Therapeutics (AMEX:PTHS) reported quarterly losses of $(6.62) per share which missed the analyst consensus estimate of $(3.05) by 117.05 percent. This is a 23.05 percent decrease over losses of $(5.38) per share from the same period last year. The company reported quarterly sales of $15.603 million which beat the analyst consensus estimate of $15.273 million by 2.16 percent.